Experiences with fibrinolysin in peripheral vascular occlusive disease
The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previous...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1960-08, Vol.6 (2), p.507-512 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 512 |
|---|---|
| container_issue | 2 |
| container_start_page | 507 |
| container_title | The American journal of cardiology |
| container_volume | 6 |
| creator | Anlyan, William G. Deaton, Hugo L. Donald, Silver |
| description | The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previously. We agree completely with a recent editorial setting down the requirements for an ideal thrombolytic agent. The present study was initiated with a note of pessimism, since previous proteolytic enzymes administered by various routes had dismally failed in our experience. |
| doi_str_mv | 10.1016/0002-9149(60)90345-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_82611050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002914960903453</els_id><sourcerecordid>82611050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-6ccaf0f754566c4ed8200237f4bb3a658ef2312119f510fda2f3f0ac512bb28e3</originalsourceid><addsrcrecordid>eNp9kFFLwzAQx4Mobk6_gUifRB-quaZJmxdBxqbCwBd9Dml6YZGurck63be33Ya-CYEQ7ve_u_wIuQR6BxTEPaU0iSWk8kbQW0lZymN2RMaQZzIGCeyYjH-RETkL4aN_AnBxSkbAMskyJsdkPvtu0TusDYboy62XkXWFd3VTbYOro_4M5XaJXlfRRgfTVdpHjTFVF9wGo9IF1AHPyYnVVcCLwz0h7_PZ2_Q5Xrw-vUwfF7Fhgq5jYYy21GY85UKYFMs86VdkmU2LgmnBc7QJgwRAWg7UljqxzFJtOCRFkeTIJuR637f1zWeHYa1WLhisKl1j0wWVJwKActqD6R40vgnBo1WtdyvttwqoGvypQY4a5ChB1c6fYn3s6tC_K1ZY_oUOwnrgYQ9g_8uNQ6-C2dkrnUezVmXj_p_wAzUkf6c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>82611050</pqid></control><display><type>article</type><title>Experiences with fibrinolysin in peripheral vascular occlusive disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anlyan, William G. ; Deaton, Hugo L. ; Donald, Silver</creator><creatorcontrib>Anlyan, William G. ; Deaton, Hugo L. ; Donald, Silver</creatorcontrib><description>The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previously. We agree completely with a recent editorial setting down the requirements for an ideal thrombolytic agent. The present study was initiated with a note of pessimism, since previous proteolytic enzymes administered by various routes had dismally failed in our experience.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/0002-9149(60)90345-3</identifier><identifier>PMID: 13793739</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular Diseases ; Fibrinolysin - therapy ; Humans ; Old Medline ; Peripheral Vascular Diseases - therapy ; Thromboembolism - therapy ; Vascular Diseases</subject><ispartof>The American journal of cardiology, 1960-08, Vol.6 (2), p.507-512</ispartof><rights>1960</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-6ccaf0f754566c4ed8200237f4bb3a658ef2312119f510fda2f3f0ac512bb28e3</citedby><cites>FETCH-LOGICAL-c360t-6ccaf0f754566c4ed8200237f4bb3a658ef2312119f510fda2f3f0ac512bb28e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9149(60)90345-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/13793739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anlyan, William G.</creatorcontrib><creatorcontrib>Deaton, Hugo L.</creatorcontrib><creatorcontrib>Donald, Silver</creatorcontrib><title>Experiences with fibrinolysin in peripheral vascular occlusive disease</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previously. We agree completely with a recent editorial setting down the requirements for an ideal thrombolytic agent. The present study was initiated with a note of pessimism, since previous proteolytic enzymes administered by various routes had dismally failed in our experience.</description><subject>Cardiovascular Diseases</subject><subject>Fibrinolysin - therapy</subject><subject>Humans</subject><subject>Old Medline</subject><subject>Peripheral Vascular Diseases - therapy</subject><subject>Thromboembolism - therapy</subject><subject>Vascular Diseases</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1960</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFFLwzAQx4Mobk6_gUifRB-quaZJmxdBxqbCwBd9Dml6YZGurck63be33Ya-CYEQ7ve_u_wIuQR6BxTEPaU0iSWk8kbQW0lZymN2RMaQZzIGCeyYjH-RETkL4aN_AnBxSkbAMskyJsdkPvtu0TusDYboy62XkXWFd3VTbYOro_4M5XaJXlfRRgfTVdpHjTFVF9wGo9IF1AHPyYnVVcCLwz0h7_PZ2_Q5Xrw-vUwfF7Fhgq5jYYy21GY85UKYFMs86VdkmU2LgmnBc7QJgwRAWg7UljqxzFJtOCRFkeTIJuR637f1zWeHYa1WLhisKl1j0wWVJwKActqD6R40vgnBo1WtdyvttwqoGvypQY4a5ChB1c6fYn3s6tC_K1ZY_oUOwnrgYQ9g_8uNQ6-C2dkrnUezVmXj_p_wAzUkf6c</recordid><startdate>196008</startdate><enddate>196008</enddate><creator>Anlyan, William G.</creator><creator>Deaton, Hugo L.</creator><creator>Donald, Silver</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>196008</creationdate><title>Experiences with fibrinolysin in peripheral vascular occlusive disease</title><author>Anlyan, William G. ; Deaton, Hugo L. ; Donald, Silver</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-6ccaf0f754566c4ed8200237f4bb3a658ef2312119f510fda2f3f0ac512bb28e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1960</creationdate><topic>Cardiovascular Diseases</topic><topic>Fibrinolysin - therapy</topic><topic>Humans</topic><topic>Old Medline</topic><topic>Peripheral Vascular Diseases - therapy</topic><topic>Thromboembolism - therapy</topic><topic>Vascular Diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anlyan, William G.</creatorcontrib><creatorcontrib>Deaton, Hugo L.</creatorcontrib><creatorcontrib>Donald, Silver</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anlyan, William G.</au><au>Deaton, Hugo L.</au><au>Donald, Silver</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experiences with fibrinolysin in peripheral vascular occlusive disease</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1960-08</date><risdate>1960</risdate><volume>6</volume><issue>2</issue><spage>507</spage><epage>512</epage><pages>507-512</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previously. We agree completely with a recent editorial setting down the requirements for an ideal thrombolytic agent. The present study was initiated with a note of pessimism, since previous proteolytic enzymes administered by various routes had dismally failed in our experience.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>13793739</pmid><doi>10.1016/0002-9149(60)90345-3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1960-08, Vol.6 (2), p.507-512 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_82611050 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Cardiovascular Diseases Fibrinolysin - therapy Humans Old Medline Peripheral Vascular Diseases - therapy Thromboembolism - therapy Vascular Diseases |
| title | Experiences with fibrinolysin in peripheral vascular occlusive disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T19%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experiences%20with%20fibrinolysin%20in%20peripheral%20vascular%20occlusive%20disease&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Anlyan,%20William%20G.&rft.date=1960-08&rft.volume=6&rft.issue=2&rft.spage=507&rft.epage=512&rft.pages=507-512&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/0002-9149(60)90345-3&rft_dat=%3Cproquest_cross%3E82611050%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=82611050&rft_id=info:pmid/13793739&rft_els_id=0002914960903453&rfr_iscdi=true |